Sirolimus Rx

Editorial standards

How this site researches, sources, updates, and corrects its rapamycin (sirolimus) content. We would rather show you the process than ask for trust.

Our review process

Every page is built from a claims ledger: each factual statement is entered as a discrete claim, matched to a primary source fetched on a recorded date, stored with the exact supporting language, and graded by evidence type (FDA label statement, human RCT, human observational, human PK, animal finding, in vitro, regulatory record, review, derived arithmetic, or documented absence of evidence). Statements about sirolimus's approval and safety rules come only from the current FDA labels and records. Study findings carry two mandatory labels in the study table: the species, and the exact compound studied, because several famous 'rapamycin' trials tested everolimus or dactolisib instead. A human-trial chip is never placed on animal data, and a sirolimus label is never placed on an everolimus result. No physician or clinician has reviewed this site, and we do not claim medical review; what we claim is that every number resolves to its cited source, and the machine-readable ledger that proves it ships with the site.

Sourcing rules

Allowed sources: FDA (labels via DailyMed and openFDA, Drugs@FDA records), PubMed-indexed peer-reviewed journals, PubMed Central and Europe PMC full texts, ClinicalTrials.gov, and PubChem. Not allowed: longevity-clinic marketing, telehealth landing pages, supplement vendors, wellness blogs, press releases, and secondary aggregators. Industry-run trials are cited with their sponsorship named in the text (PEARL is an AgelessRx trial and we say so). Where the honest answer is an absence (no human longevity outcome trial, no valid mouse-to-human dose conversion), we cite the studies that establish the absence and say so plainly.

Update policy

Each page displays its published and last-updated dates. We re-review this compound's pages when any of the following changes: the sirolimus label (new SPL version under NDA 021083 or 021110), FDA action on any sirolimus application, publication of a randomized sirolimus or rapalog trial in an aging population, or new ITP lifespan results. Scheduled re-checks include re-resolving every citation link. Material changes get a dated note on the affected page.

Corrections and feedback

If we got something wrong, we want it gone. Use the corrections link in the site footer and include the page URL and the claim you dispute. Verified corrections are made on the page with a dated note; claims that fail re-verification are removed from the ledger and from every surface that rendered them. We regard a citation that does not support its claim as the most serious defect this site can have.

Start provider review